Abstract
Fingolimod is a an oral disease modifying drug for relapsing remitting multiple sclerosis (MS) preventing egress of B and T cells from lymph nodes. Relevant first dose adverse events include bradycardia and atrioventricular conduction slowing. Cardiac side effects of fingolimod and combinational pharmacotherapy including duloxetine and tolterodine were monitored in mice of different age using implantable ECG telemetric systems. Cardiac tissue was assessed for S1P-receptor subtype (1 and 3), and for GIRK1 expression. Fingolimod led to a significant heart rate reduction within 60 min, which returned to baseline values within 24 h. In older mice bradycardia was more pronounced compared to younger mice. Atrioventricular conduction was not affected. Older mice showed a higher S1PR3 expression in a naïve state and receptor expression was reduced after fingolimod administration. Combination with duloxetine or tolterodine alleviated fingolimod induced heart rate decrease. Our data provide preclinical evidence that negative chronotropic effects of fingolimod might be age dependent, possibly due to an altered expression and internalization of cardiac S1PR3 in older animals. This data could be relevant for future clinical monitoring and patient selection in the aging MS population. Combinational therapies of fingolimod and duloxetine or tolterodine are well tolerated and safe without an increased risk for pronounced bradycardia or arrhythmia.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Andersson KE (2004) Antimuscarinics for treatment of overactive bladder. Lancet Neurol 3:46–53
Andersson KE, Olshansky B (2007) Treating patients with overactive bladder syndrome with antimuscarinics: heart rate considerations. BJU Int 100:1007–1014
Arnon TI, Xu Y, Lo C, Pham T, An J, Coughlin S, Dorn GW, Cyster JG (2011) GRK2-dependent S1PR1 desensitization is required for lymphocytes to overcome their attraction to blood. Science 333:1898–1903
Brinkmann V, Davis MD, Heise CE, Albert R, Cottens S, Hof R, Bruns C, Prieschl E, Baumruker T, Hiestand P, Foster CA, Zollinger M, Lynch KR (2002) The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem 277:21453–21457
Budde K, Schmouder RL, Brunkhorst R, Nashan B, Lucker PW, Mayer T, Choudhury S, Skerjanec A, Kraus G, Neumayer HH (2002) First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients. J Am Soc Nephrol: JASN 13:1073–1083
Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, Pelletier J, Capra R, Gallo P, Izquierdo G, Tiel-Wilck K, de Vera A, Jin J, Stites T, Wu S, Aradhye S, Kappos L (2010) Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 362:402–415
de Seze M, Ruffion A, Denys P, Joseph PA, Perrouin-Verbe B (2007) The neurogenic bladder in multiple sclerosis: review of the literature and proposal of management guidelines. Mult Scler 13:915–928
Estrada R, Zeng Q, Lu H, Sarojini H, Lee JF, Mathis SP, Sanchez T, Wang E, Kontos CD, Lin CY, Hla T, Haribabu B, Lee MJ (2008) Up-regulating sphingosine 1-phosphate receptor-2 signaling impairs chemotactic, wound-healing, and morphogenetic responses in senescent endothelial cells. J Biol Chem 283:30363–30375
Forrest M, Sun SY, Hajdu R, Bergstrom J, Card D, Doherty G, Hale J, Keohane C, Meyers C, Milligan J, Mills S, Nomura N, Rosen H, Rosenbach M, Shei GJ, Singer II, Tian M, West S, White V, Xie J, Proia RL, Mandala S (2004) Immune cell regulation and cardiovascular effects of sphingosine 1-phosphate receptor agonists in rodents are mediated via distinct receptor subtypes. J Pharmacol Exp Ther 309:758–768
Fowler CJ, Panicker JN, Drake M, Harris C, Harrison SC, Kirby M, Lucas M, Macleod N, Mangnall J, North A, Porter B, Reid S, Russell N, Watkiss K, Wells M (2009) A UK consensus on the management of the bladder in multiple sclerosis. Postgrad Med J 85:552–559
Gold R, Comi G, Palace J, Siever A, Gottschalk R, Bijarnia M, von Rosenstiel P, Tomic D, Kappos L (2014) Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study. J Neurol 261:267–276
Jasiak NM, Bostwick JR (2014) Risk of QT/QTc prolongation among newer non-SSRI antidepressants. Ann Pharmacother 48:1620–1628
Koyrakh L, Roman MI, Brinkmann V, Wickman K (2005) The heart rate decrease caused by acute FTY720 administration is mediated by the G protein-gated potassium channel I. Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg 5:529–536
Lu H, Yuan H, Chen S, Huang L, Xiang H, Yang G, Deng H, Zhou J (2012) Senescent endothelial dysfunction is attributed to the up-regulation of sphingosine-1-phosphate receptor-2 in aged rats. Mol Cell Biochem 363:217–224
Olshansky B, Serra DB (2008) Thorough QT study with recommended and supratherapeutic doses of tolterodine. Clin Pharmacol Ther 83:231–232 author reply 233
Rosen H, Gonzalez-Cabrera PJ, Sanna MG, Brown S (2009) Sphingosine 1-phosphate receptor signaling. Annu Rev Biochem 78:743–768
Sanna MG, Liao J, Jo E, Alfonso C, Ahn MY, Peterson MS, Webb B, Lefebvre S, Chun J, Gray N, Rosen H (2004) Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate. J Biol Chem 279:13839–13848
Schiffers M, Sauermann P, Schurch B, Mehnert U (2010) The effect of tolterodine 4 and 8 mg on the heart rate variability in healthy subjects. World J Urol 28:651–656
Sugiyama A, Yatomi Y, Ozaki Y, Hashimoto K (2000) Sphingosine 1-phosphate induces sinus tachycardia and coronary vasoconstriction in the canine heart. Cardiovasc Res 46:119–125
Vanoli E, Pentimalli F, Botto G (2014) Vagomimetic effects of fingolimod: physiology and clinical implications. CNS Neurosci Ther 20:496–502
Xue F, Strombom I, Turnbull B, Zhu S, Seeger J (2012) Treatment with duloxetine in adults and the incidence of cardiovascular events. J Clin Psychopharmacol 32:23–30
Acknowledgements
The study was funded by a grant from Novartis Pharma AG and a university grant (Career Advancement Program, Center of Molecular Medicine, University of Cologne, to H.C. L).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interests
Nothing to declare.
Additional information
Christian Ritter and Martin K. R. Svačina contributed equally.
Rights and permissions
About this article
Cite this article
Ritter, C., Svačina, M.K.R., Bobylev, I. et al. Impact of Age and Polytherapy on Fingolimod Induced Bradycardia: a Preclinical Study. J Neuroimmune Pharmacol 12, 204–209 (2017). https://doi.org/10.1007/s11481-017-9727-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11481-017-9727-8